

Box 502
Seahorse
12

Atty. Dkt. No. 058333-0106



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Sunghoon Kim et al.

Title: IMMUNOLOGICAL ENHANCEMENT AGENT
COMPRISING N-TERMINAL PEPTIDE OF P43
AS AN EFFECTIVE COMPONENT

Appl. No.: 09/930,169

Filing Date: August 16, 2001

Examiner: Unassigned

Art Unit: Unassigned

**TRANSMITTAL OF MISSING PARTS
OF PATENT APPLICATION**

Commissioner for Patents
Washington, D.C. 20231

Attn: BOX MISSING PARTS

Sir:

In response to the Notice to File Missing Parts of Application mailed on September 21, 2001, in the above-identified application, transmitted herewith are the missing parts needed to complete the filing of the subject patent application.

Enclosed are:

- [X] Declaration and Power of Attorney (4 pages);
- [X] Claim for Convention Priority with (1) Priority Document;
- [X] Statement to Support Filing and Submission In Accordance with 37 C.F.R. §1.821-1.825 of Sequence Listing;
- [X] Paper copy of Sequence Listing;
- [X] Readable Diskette;
- [X] Copy of Notice to File Missing Parts (Part 2 of Form PTO-1533).

The filing fee is calculated below:

	Claims as Filed	Included in Basic Fee	Extra Claims	Rate	Fee Totals
Basic Fee				\$740.00	\$740.00
Total Claims:	3	- 20	= 0	x \$18.00	= \$0.00
Independents:	3	- 3	= 0	x \$84.00	= \$0.00
If any Multiple Dependent Claim(s) present:				+ \$280.00	= \$0.00
Surcharge under 37 CFR 1.16(e) for late filing of Executed Declaration and late payment of filing fee				+ \$130.00	= \$130.00
				SUBTOTAL:	= \$870.00
[X] Small Entity Fees Apply (subtract ½ of above):					= \$435.00
				TOTAL FILING FEE:	= \$435.00
				TOTAL FEE	= \$435.00
Difference to pay:				\$0.00	= \$435.00

[X] Check in the amount of \$435.00 in payment of \$370.00 for the official Government filing fee and \$65.00 for surcharge fee (37 C.F.R. § 1.16(e))

[] Please charge Deposit Account No. 19-0741 in the amount of \$435.00 in payment of surcharge fee (37 C.F.R. § 1.16(e))

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date November 6, 2001

By



FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5109
Telephone: (202) 672-5404
Facsimile: (202) 672-5399

Stephen A. Bent
Attorney for Applicant
Registration No. 29,768



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket No: 058333/0106

In patent application of

KIM, SUNGHOON et al.

Serial No. 09/930,169

Filed: August 16, 2001

For: IMMUNOLOGICAL ENHANCEMENT AGENT COMPRISING N-TERMINAL PEPTIDE OF P43
AS AN EFFECTIVE COMPONENT

4

STATEMENT TO SUPPORT FILING AND SUBMISSION IN
ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825

Assistant Commissioner for Patents
Washington, D.C. 20231
Box SEQUENCE

Sir:

In connection with a Sequence Listing submitted concurrently herewith, the undersigned hereby states that:

1. the submission, filed herewith in accordance with 37 C.F.R. § 1.821(g), does not include new matter;

2. the content of the attached paper copy and the attached computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same; and


3. all statements made herein of their own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United

Serial No. 09/930,169

States Code and that such willful false statements may jeopardize the validity of the application or any patent resulting therefrom.

Respectfully submitted,

Oct. 23, 2001
Date



James A. Coburn

HARBOR CONSULTING
Intellectual Property Services
1500A Lafayette Road
Suite 262
Portsmouth, N.H.
800-318-3021



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Sunghoon Kim et al.
Title: IMMUNOLOGICAL ENHANCEMENT AGENT
COMPRISING N-TERMINAL PEPTIDE OF P43
AS AN EFFECTIVE COMPONENT

Appl. No.: 09/930,169

Filing Date: August 16, 2001

Examiner: Unassigned

Art Unit: Unassigned

CLAIM FOR CONVENTION PRIORITY

Commissioner for Patents
Washington, D.C. 20231

Sir:

The benefit of the filing date of the following prior foreign application filed in the following foreign country is hereby requested, and the right of priority provided in 35 U.S.C. § 119 is hereby claimed.

In support of this claim, filed herewith is a certified copy of said original foreign application:

- Korean Patent Application No. 2001-31310 filed June 5, 2001.

Respectfully submitted,

Date November 6, 2001

By Stephen A. Bent

FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5109
Telephone: (202) 672-5404
Facsimile: (202) 672-5399

Stephen A. Bent
Attorney for Applicant
Registration No. 29,768



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/930,169	08/16/2001	Sunghoon Kim	058333-0106

CONFIRMATION NO. 1098

FORMALITIES LETTER



OC000000006589865

Stephen A. Bent
FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, DC 20007-5109

Date Mailed: 09/21/2001

NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

Filing Date Granted

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given **TWO MONTHS** from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The oath or declaration is unsigned.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(e) of \$65 for a small entity in compliance with 37 CFR 1.27, must be submitted with the missing items identified in this letter.
- **The balance due by applicant is \$ 65.**
- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

11/07/2001 YPOLITE1 00000064 09930169

01 FC:205

65.00 OP

Repln. Ref: 11/07/2001 YPOLITE1 0013082300
 DB: 190741 Name/Number: 09930169
 FC: 704 \$370.00 CR

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*



Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE